Literature DB >> 33044780

Relationship of Patent Ductus Arteriosus Echocardiographic Markers With Descending Aorta Diastolic Flow.

Fernando de Freitas Martins1, Diego G Bassani2, Daniel Ibarra Rios1, Maura Helena F Resende3, Dany Weisz4, Amish Jain5, Jose Maria de Andrade Lopes1, Patrick J McNamara6.   

Abstract

OBJECTIVES: To characterize the relationship of echocardiographic markers of left heart overload and flow in peripheral major end-organ vessels (eg, celiac artery) with the presence of reversed holodiastolic flow in the descending aorta, considered a surrogate marker of an increased transductal shunt volume, in preterm patients with a patent ductus arteriosus (PDA).
METHODS: This work was a retrospective study of data from echocardiography performed to investigate the hemodynamic significance of a PDA in preterm patients. We studied differences in echocardiographic markers of the PDA shunt volume according to patterns of flow in the postductal descending aorta (no PDA, PDA with antegrade diastolic flow, and PDA with reversed diastolic flow). The strength of the association between each echocardiographic marker and the presence of aortic holodiastolic flow reversal was investigated.
RESULTS: We studied 137 patients with a median (interquartile range) birth weight of 850 (694-1030) g and a median gestational age of 25 (24-27) weeks. Among patients with a PDA (113), those with diastolic flow reversal in the descending aorta (44) presented had increased echocardiographic markers representative of the shunt volume (increased left ventricular output, left atrial-to-aortic ratio, pulmonary vein D wave, and shorter isovolumic relaxation time) compared to those with aortic antegrade diastolic flow. A positive, albeit weak, correlation between diastolic flow reversal and shunt volume echocardiographic markers was found. Abnormal diastolic flow in the celiac artery had the strongest correlation (R2  = 0.24).
CONCLUSIONS: In preterm patients with a PDA, echocardiographic markers of the shunt volume were more abnormal in patients with reversed diastolic flow in the descending aorta. These data support the assumption that variance in these markers are related to the shunt volume, which needs consideration when adjudicating hemodynamic significance.
© 2020 American Institute of Ultrasound in Medicine.

Entities:  

Keywords:  hemodynamic significance; patent ductus arteriosus, preterm; targeted neonatal echocardiography; transductal shunt volume

Mesh:

Substances:

Year:  2020        PMID: 33044780     DOI: 10.1002/jum.15528

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  4 in total

Review 1.  Point-of-care lung ultrasound for the assessment of pneumonia: a narrative review in the COVID-19 era.

Authors:  Toru Kameda; Yoshihiro Mizuma; Hayato Taniguchi; Masato Fujita; Nobuyuki Taniguchi
Journal:  J Med Ultrason (2001)       Date:  2021-01-13       Impact factor: 1.314

2.  One-month outcomes of patients with SARS-CoV-2 infection and their relationships with lung ultrasound signs.

Authors:  Thiago Thomaz Mafort; Rogério Rufino; Claudia Henrique da Costa; Mariana Soares da Cal; Laura Braga Monnerat; Patrícia Frascari Litrento; Laura Lizeth Zuluaga Parra; Arthur de Sá Earp de Souza Marinho; Agnaldo José Lopes
Journal:  Ultrasound J       Date:  2021-04-09

3.  Is lung ultrasound score a useful tool to monitoring and handling moderate and severe COVID-19 patients in the general ward? An observational pilot study.

Authors:  Marco Baciarello; Andrea Bonetti; Luigi Vetrugno; Francesco Saturno; Antonio Nouvenne; Valentina Bellini; Tiziana Meschi; Elena Bignami
Journal:  J Clin Monit Comput       Date:  2021-05-04       Impact factor: 1.977

4.  Early Role of the Atrial-Level Communication in Premature Infants with Patent Ductus Arteriosus.

Authors:  Danielle R Rios; Fernando de Freitas Martins; Afif El-Khuffash; Dany E Weisz; Regan E Giesinger; Patrick J McNamara
Journal:  J Am Soc Echocardiogr       Date:  2020-11-20       Impact factor: 5.251

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.